| Identification | Back Directory | [Name]
N-(5-(1-(2,6-dichlorophenyl)-3-(difluoroMethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyraMide | [CAS]
1338247-35-0 | [Synonyms]
LIMKI-3
CS-2190
BMS-5 ≥95%
BMS 5;BMS5
BMS-5， LIMKI-3
LIMKI-3;BMS5;BMS 5;LIMKI3;LIMKI 3
N-(5-(1-(2,6-dichlorophenyl)-3-(difluoroMethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyraMide
N-[5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-methylpropanamide
Propanamide, N-[5-[1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-methyl-
N-{5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]- 1,3-thiazol-2-yl}-2-methylpropanamide
Mitoquinone mesylateN-{5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]- 1,3-thiazol-2-yl}-2-methylpropanamide | [Molecular Formula]
C17H14Cl2F2N4OS | [MDL Number]
MFCD17019327 | [MOL File]
1338247-35-0.mol | [Molecular Weight]
431.29 |
| Chemical Properties | Back Directory | [density ]
1.54±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
DMSO:PBS (pH 7.2) (1:5):0.2(Max Conc. mg/mL);0.46(Max Conc. mM)
Ethanol:3.0(Max Conc. mg/mL);6.96(Max Conc. mM) | [form ]
White powder. | [pka]
9.51±0.50(Predicted) | [color ]
White to off-white | [InChI]
1S/C17H14Cl2F2N4OS/c1-8(2)16(26)23-17-22-7-13(27-17)12-6-11(15(20)21)24-25(12)14-9(18)4-3-5-10(14)19/h3-8,15H,1-2H3,(H,22,23,26) | [InChIKey]
IVUGBSGLHRJSSP-UHFFFAOYSA-N | [SMILES]
ClC1=CC=CC(Cl)=C1N2N=C(C=C2C3=CN=C(NC(C(C)C)=O)S3)C(F)F |
| Hazard Information | Back Directory | [Uses]
LIMKi 3 is a LIM kinase 1 (LIMK1) inhibitor that has antitumor properties. | [Definition]
ChEBI: LimKi 3 is a member of the class of pyrazoles that is 1-(2,6-dichlorophenyl)-1H-pyrazole which is substituted by a difluoromethyl group at position 3 and by a 2-(isobutyrylamino)-1,3-thiazol-5-yl group at position 5. It is a a potent cell-permeable inhibitor of LIM kinase 1 and 2. It has a role as a LIM kinase inhibitor. It is a member of pyrazoles, a member of 1,3-thiazoles, a dichlorobenzene, an organofluorine compound and a secondary carboxamide. | [Biological Activity]
Cell permeable: yes''Primary Target
LIMK1 and LIMK2''Reversible: yes''Secondary Target
AMPKA1AMPKA2DDR1PAK3DCAMKL2''Target IC50: 7 and 8 nM against LIMK1 and LIMK2respectively | [in vivo]
BMS-5 (LIMKi 3) (20 or 200 μM/side) is bilaterally infused into the hippocampus of rats immediately after contextual fear conditioning training. Rats are tested for memory consolidation 48 h after fear conditioning. Post hoc analysis shows that the group treated with 200 μM BMS-5 express lower freezing levels compared to the 20 μM and vehicle groups (P<0.01)[3]. | [IC 50]
LIMK1: 7 nM (IC50); LIMK2: 8 nM (IC50) | [storage]
Store at +4°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|